AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance

AngioDynamics (NASDAQ:ANGO - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of -0.350--0.250 for the period, compared to the consensus earnings per share estimate of -0.227. The company issued revenue guidance of $305.0 million-$310.0 million, compared to the consensus revenue estimate of $304.9 million.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ANGO. Canaccord Genuity Group set a $17.00 price target on shares of AngioDynamics and gave the stock a "buy" rating in a report on Wednesday. Lake Street Capital began coverage on shares of AngioDynamics in a report on Wednesday. They issued a "buy" rating and a $24.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of AngioDynamics in a report on Wednesday.

AngioDynamics Stock Performance

ANGO traded down $0.05 on Wednesday, reaching $8.60. The company had a trading volume of 2,249,198 shares, compared to its average volume of 590,674. The business has a 50 day simple moving average of $9.88 and a 200 day simple moving average of $10.07. The company has a market cap of $349.25 million, a price-to-earnings ratio of -10.36 and a beta of 0.60. AngioDynamics has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The business had revenue of $80.16 million for the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.17%. AngioDynamics's quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm posted ($0.06) earnings per share. As a group, equities research analysts predict that AngioDynamics will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

An institutional investor recently raised its position in AngioDynamics stock. Goldman Sachs Group Inc. raised its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 9.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 259,226 shares of the medical instruments supplier's stock after acquiring an additional 22,658 shares during the period. Goldman Sachs Group Inc. owned about 0.64% of AngioDynamics worth $2,434,000 at the end of the most recent reporting period. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.